

Edgar Filing: GENEREX BIOTECHNOLOGY CORP - Form 8-K

GENEREX BIOTECHNOLOGY CORP
Form 8-K
June 05, 2003

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported) May 29, 2003

Generex Biotechnology Corporation

(Exact name of registrant as specified in its charter)

Delaware ----- (State or other jurisdiction of Incorporation)	000-25169 ----- (Commission File Number)	82-049021 ----- (IRS Employer Identification No.)
--	---	--

33 Harbor Square, Suite 202, Toronto, Ontario Canada M5J 2G2

(Address of principal executive offices) (Zip Code)

Registrant's telephone number, including area code 416/364-2551

(Former name or former address, if changed since last report)

Item 5. Other Events

On June 2, 2003, Generex Biotechnology Corporation issued a press release announcing that the Company raised \$3,215,000, with net proceeds of \$3,000,000, in a private placement of its unregistered common stock. Under the terms of the transaction, Generex issued 2,795,652 shares of common stock to accredited institutional investors. A copy of the press release is attached hereto as Exhibit 99.1 and incorporated herein by reference.

Edgar Filing: GENEREX BIOTECHNOLOGY CORP - Form 8-K

(c) Exhibits

Exhibit No. -----	Description -----
99.1	Press release dated May 29, 2003.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

GENEREX BIOTECHNOLOGY CORPORATION

Dated: June 5, 2003

By: Rose C. Perri

Rose C. Perri
Chief Operating Officer
(principal financial officer)

Exhibit Index

Exhibit No. -----	Description -----
99.1	Press release dated May 29, 2003